Solid 4Q17/FY18 guide, questions on pharma
JNJ reported 4Q17 sales of $20.2b were slightly ahead of consensus on better than expected sales in MD&D. Pharma revenues were a touch ahead, but sales for Remicade slipped on biosimilar competition. FY18 guidance for adjusted revenue growth of 4% and adj. EPS growth of 8.2% appear to be modestly ahead of consensus. Key issues on the call are likely to be outlook for Remicade, potential generic pressure on Zytiga, status of key pipeline updates and tax and the non-operating income benefit to FY18 EPS guidance.Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a range of products in the health care field. The company has three business segments: Consumer, which includes a range of products focused on personal healthcare used in the beauty, over-the-counter pharmaceutical, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension; and Medical Devices, which includes products used in the orthopaedic, surgery, interventional solutions, and eye health fields.
Formed in 2003 by an established team from Cazenove, one of the most respected investment banks in the UK, Atlantic Equities conducts and publishes fundamental, bottom up research on mid and large cap US companies.
Atlantic provide order execution through a wide range of DMA products and algorithmic trading suites.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.